Anula Jayasuriya appointed to Board of Directors of Lineage Cell Therapeutics

By: WE Staff | Thursday, 6 May 2021

Anula Jayasuriya, M.D., Ph.D., M.B.A., has been appointed to the Board of Directors of Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company developing innovative cell transplants for severe medical conditions.

Lineage uses pluripotent and progenitor cell starting materials to produce and manufacture specialised, terminally differentiated human cells.

Dr. Jayasuriya is an experienced healthcare private equity executive and venture capitalist with a diverse background in clinical, industry, entrepreneurship, and investment.

Dr. Jayasuriya is the Founder and Managing Director of EXXclaim Capital, an early-stage venture fund focusing on catalysing innovation, entrepreneurship, and investment in women's health, as well as a Co-Founder of Evolvence India Life Science Fund (EILSF), India's first fund to focus solely on healthcare and invest in Indian pharmaceutical, biotechnology, medical device, and contract services companies.

Dr. Jayasuriya holds a B.A. with honours from Harvard University, an M. Phil. in pharmacology from the University of Cambridge, an M.D. and Ph.D. (in Microbiology and Molecular Genetics) from Harvard Medical School, and an M.B.A. with honours from Harvard Business School.

“Dr. Jayasuriya is a successful healthcare investment executive with deep insights and experience in the clinical development of a wide range of medical products. We are delighted she will be joining our Board of Directors,” stated Al Kingsley, Lineage’s Chairman of the Board.

Kingsley added, “Dr. Jayasuriya’s appointment reflects an overall commitment to ensuring that our Board reflects a broad range of expertise and perspectives as Lineage works to position itself as a leader in the field of cell therapy and regenerative medicine.”

“I am excited to join Lineage’s Board at a transformational time in the Company’s history,” stated Dr. Jayasuriya.“Lineage is pioneering a new branch of medicine by advancing its off-the-shelf cell transplant therapies toward later-stage clinical trials. These products have the potential to address multi-billion-dollar market opportunities and greatly improve the lives of patients. I look forward to helping the Company as it positions itself for success in 2021 and beyond.”